





- (51) **International Patent Classification:**  
*C07D 413/14* (2006.01) *A61P 35/00* (2006.01)  
*A61K 31/5377* (2006.01)
- (21) **International Application Number:**  
PCT/CA2014/051001
- (22) **International Filing Date:**  
17 October 2014 (17.10.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
61/892,564 18 October 2013 (18.10.2013) US
- (71) **Applicant:** UNIVERSITY HEALTH NETWORK [CA/CA]; 190 Elizabeth Street, R. Fraser Elliott Building - Room 1S-417, Toronto, Ontario M5G 2C4 (CA).
- (72) **Inventors:** SAMPSON, Peter Brent; 1320 Ridgebank Drive, Oakville, Ontario L6M 4A5 (CA). FEHER, Miklos; 229 West 60th Street, Apt. 22M, New York, New York 10023 (US). PAULS, Heinz W.; 460 Fourth Line, Oakville, Ontario L6L 5A4 (CA).
- (74) **Agents:** BAKER, James D. et al.; Gowling Lafleur Henderson LLP, 160 Elgin Street, Suite 2600, Ottawa, Ontario K1P 1C3 (CA).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

## (54) Title: SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR

Figure 1. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino) methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form A



(57) **Abstract:** A fumarate salt and a maleate salt of compound (I) represented by the following structural formula, as well as their corresponding pharmaceutical compositions, are disclosed. Particular single crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are characterized by a variety of properties and physical measurements. Methods of preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate are also disclosed. The present invention also provides methods of treating a subject with a cancer. Compound (I)

**Declarations under Rule 4.17:**

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

**Published:**

- *with international search report (Art. 21(3))*


## SALT AND CRYSTAL FORMS OF PLK-4 INHIBITOR

### RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/892,564  
5 filed October 18, 2013, the entire teachings of which are incorporated herein by reference.

### BACKGROUND

The polo-like kinase (PLK) family of serine/threonine kinases comprises at least four  
known members: PLK1, PLK2 (also known as Snk), PLK3 (also known as Fnk or Prk) and  
PLK4 (also known as Sak). Agents which inhibit PLK4 have the potential to treat cancer. A  
10 number of potent PLK4 inhibitors are disclosed in U.S. Patent Nos. 8,263,596, 8,481,525,  
and 8,481,533 (the entire teachings of which are incorporated herein by reference). The  
structure of one inhibitor disclosed in these patents is shown below as compound (I):



There is a need for salt forms of this compound that are crystalline and otherwise have  
15 physical properties that are amenable to large scale manufacture. There is also a need for  
pharmaceutical formulations in which this drug candidate is stable and is effectively  
delivered to the patient.

### SUMMARY OF THE INVENTION

It has been found that the 1:1 fumaric acid salt and the 1:1 maleic acid salt of  
20 compound (I) can be crystallized under well-defined conditions to provide non-hygroscopic  
crystalline forms. The designation "1:1" is the molar ratio between acid (fumaric or maleic)  
and compound (I). Because of the two carboxylic acid groups on fumaric acid and maleic  
acid, it is also possible to form a 1:2 fumaric acid salt and a 1:2 maleic acid salt of compound  
(I), in which the molar ratio between acid (fumaric or maleic) and compound (I) is 1:2. The  
25 1:1 fumaric acid salt of compound (I) is referred to herein as "1:1 compound (I) fumarate";  
and the 1:1 maleic acid salt is referred to herein as "1:1 compound (I) maleate".

1:1 Compound (I) fumarate and 1:1 compound (I) maleate have several advantageous properties when compared with other salts of compound (I). As shown in Examples 1 and 2, many salts of compound (I), including hydrochloride salt, phosphate, sulfate, and citrate, could not be obtained in crystal form. Notably, 1:2 compound (I) fumarate and 1:2 compound (I) maleate also could not be obtained in crystalline form. 1:1 Compound (I) fumarate and 1:1 compound (I) maleate are both non-hygroscopic and easier to formulate than the free base and the other salts. Thus, these favorable properties make 1:1 compound (I) fumarate and 1:1 compound (I) maleate amenable to large scale manufacture and formulation as a drug candidate.

10 In one aspect, the present invention provides a fumarate salt of compound (I) wherein the molar ratio between compound (I) and fumaric acid is 1:1. As noted above, this salt is also referred to herein as “1:1 compound (I) fumarate”.

In another aspect, the present invention provides a maleate salt of compound (I) wherein the molar ratio between compound (I) and maleic acid is 1:1. As noted above, this salt is also referred to herein as “1:1 compound (I) maleate”.

15 In another aspect, the present invention provides a pharmaceutical composition comprising 1:1 compound (I) fumarate (or 1:1 compound (I) maleate) and a pharmaceutically acceptable carrier or diluent.

In still another aspect, the present invention provides a method of treating a subject with cancer, comprising administering to the subject an effective amount of 1:1 compound (I) fumarate or 1:1 compound (I) maleate.

The present invention provides a method of inhibiting PLK4 activity in a subject in need of inhibition of PLK4 activity, comprising administering to the subject an effective amount of 1:1 compound (I) fumarate or 1:1 compound (I) maleate.

25 The present invention also provides 1:1 compound (I) fumarate or 1:1 compound (I) maleate for use in medicinal therapy. In one embodiment, the medicinal therapy is for treating a subject with cancer. Alternatively, the therapy is for inhibiting PLK4 activity in a subject in need of inhibition of PLK4 activity.

Another aspect of the present invention is the use of 1:1 compound (I) fumarate or 1:1 compound (I) maleate for the manufacture of a medicament for treating a subject with cancer.

Another aspect of the present invention is 1:1 compound (I) fumarate or 1:1 compound (I) maleate for treating a subject with cancer.

Another aspect of the present invention is the use of a 1:1 compound (I) fumarate or 1:1 compound (I) maleate for the manufacture of a medicament for inhibiting PLK4 activity in a subject in need of inhibition of PLK4 activity.

Another aspect of the present invention is 1:1 compound (I) fumarate or 1:1  
5 compound (I) maleate for inhibiting PLK4 activity in a subject in need of inhibition of PLK4 activity.

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows the Differential Scanning Calorimetry Analysis (DSC) thermogram for form A of 1:1 compound (I) fumarate.

10 Figure 2 shows the DSC thermogram for form B of 1:1 compound (I) fumarate.

Figure 3 shows the DSC thermogram for form C of 1:1 compound (I) fumarate.

Figure 4 shows the DSC thermogram for form D of 1:1 compound (I) fumarate.

Figure 5 shows the DSC thermogram for form A of 1:1 compound (I) maleate.

Figure 6 shows the DSC thermogram for phosphate of compound (I).

15 Figure 7 shows the X-ray Powder Diffraction (XRPD) pattern for form A of 1:1 compound (I) fumarate.

Figure 8 shows the XRPD pattern for form B of 1:1 compound (I) fumarate.

Figure 9 shows the XRPD pattern for form C of 1:1 compound (I) fumarate.

Figure 10 shows the XRPD pattern for form D of 1:1 compound (I) fumarate.

20 Figure 11 shows the XRPD pattern for form A of 1:1 compound (I) maleate.

#### DETAILED DESCRIPTION OF THE INVENTION

The present invention provides 1:1 compound (I) fumarate, 1:1 compound (I) maleate, unique crystalline forms thereof and their corresponding pharmaceutical compositions. The present invention also provides methods of treating a subject with a cancer. Additionally, the  
25 present invention provides methods for preparing specific crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate.

#### *Crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate*

In a particular embodiment, at least a particular percentage by weight of 1:1  
30 compound (I) fumarate or 1:1 compound (I) maleate is crystalline. Particular weight percentages include 70%, 72%, 75%, 77%, 80%, 82%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a weight percentage of

70%-75%, 75%-80%, 80%-85%, 85%-90%, 90%-95%, 95%-100%, 70-80%, 80-90%, 90-100%. For example, in one embodiment, at least 80% (*e.g.*, at least 90% or 99%) by weight of the 1:1 compound (I) fumarate or the 1:1 compound (I) maleate is crystalline. It is to be understood that all values and ranges between these values and ranges are meant to be encompassed by the present invention.

In another particular embodiment, at least a particular percentage by weight of 1:1 compound (I) fumarate and 1:1 compound (I) maleate is a single crystalline form. Particular weight percentages include 70%, 72%, 75%, 77%, 80%, 82%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, 99.5%, 99.9%, or a weight percentage of 70%-75%, 75%-80%, 80%-85%, 85%-90%, 90%-95%, 95%-100%, 70-80%, 80-90%, 90-100%. For example, in one embodiment, at least 80% (*e.g.*, at least 90% or 99%) by weight of the 1:1 compound (I) fumarate and 1:1 compound (I) maleate is in a single crystalline form. It is to be understood that all values and ranges between these values and ranges are meant to be encompassed by the present invention.

As used herein, "crystalline" refers to a solid having a crystal structure wherein the individual molecules have a highly homogeneous regular locked-in chemical configuration. Crystalline 1:1 compound (I) fumarate and crystalline 1:1 compound (I) maleate can be crystals of a single crystalline form of 1:1 compound (I) fumarate and 1:1 compound (I) maleate, or a mixture of crystals of different single crystalline forms. A single crystalline form means 1:1 compound (I) fumarate or 1:1 compound (I) maleate as a single crystal or a plurality of crystals in which each crystal has the same crystal form.

When a particular percentage by weight of 1:1 compound (I) fumarate (or 1:1 compound (I) maleate) is a single crystalline form, the remainder of the fumarate (or 1:1 compound (I) maleate) is some combination of amorphous fumarate (or 1:1 compound (I) maleate), and/or one or more other crystalline forms of 1:1 compound (I) fumarate (or 1:1 compound (I) maleate) excluding the single crystalline form. When the crystalline 1:1 compound (I) fumarate (or crystalline 1:1 compound (I) maleate) is defined as a specified percentage of one particular crystalline form of 1:1 compound (I) fumarate (or 1:1 compound (I) maleate), the remainder is made up of amorphous form and/or crystalline forms other than the one or more particular forms that are specified. Examples of a single crystalline form include form A of 1:1 compound (I) fumarate (or 1:1 compound (I) maleate) characterized by one or more properties as discussed herein.

1:1 Compound (I) fumarate (or 1:1 compound (I) maleate) is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers, i.e., the ratio of the weight of the stereoisomer over the weight of all the stereoisomers.

5 *Preparation of crystalline forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate*

The particular solid forms of 1:1 compound (I) fumarate or 1:1 compound (I) maleate can be prepared, for example, by slow evaporation, slow cooling, and antisolvent precipitation.

As used herein, "anti-solvent" refers to a solvent, in which 1:1 compound (I) fumarate or 1:1 compound (I) maleate has low solubility and cause the fumarate or maleate to precipitate out of solution in the form of fine powder or crystals.

Alternatively, 1:1 compound (I) fumarate or 1:1 compound (I) maleate can then be recrystallized from a suitable solvent with or without the addition of a seed crystal.

The preparation of each specific solid forms of 1:1 compound (I) fumarate or 1:1 compound (I) maleate is described in the experimental section below.

*Characterization of Crystalline Forms of 1:1 compound (I) fumarate and 1:1 compound (I) maleate*

Samples are irradiated with copper K-alpha X-rays with the X-ray tube operated at 40 kV/30 mA. In one embodiment, 1:1 compound (I) fumarate is a single crystalline form, form A. In a specific embodiment, form A of 1:1 compound (I) fumarate is characterized by the X-ray powder diffraction pattern shown in Figure 7. In a more particular embodiment, 1:1 compound (I) fumarate form A is characterized by an X-ray powder diffraction pattern which comprises peaks ( $2\theta$  angles) at:

- a)  $9.7^\circ$ ,  $16.7^\circ$ , and  $20.1^\circ \pm 0.2$  in  $2\theta$  (major peaks); or  
b)  $8.2^\circ$ ,  $9.7^\circ$ ,  $16.7^\circ$ , and  $20.1^\circ \pm 0.2$  in  $2\theta$ ; or  
c)  $8.2^\circ$ ,  $9.7^\circ$ ,  $10.7^\circ$ ,  $11.5^\circ$ ,  $14.9^\circ$ ,  $16.7^\circ$ ,  $20.1^\circ$ , and  $23.5^\circ \pm 0.2$  in  $2\theta$ ; or  
d)  $8.2^\circ$ ,  $9.7^\circ$ ,  $10.7^\circ$ ,  $11.5^\circ$ ,  $13.6^\circ$ ,  $14.9^\circ$ ,  $16.7^\circ$ ,  $18.1^\circ$ ,  $18.8^\circ$ ,  $20.1^\circ$ ,  $23.5^\circ$ , and  $24.5^\circ \pm 0.2$  in  $2\theta$ .

The major peaks described herein have a relative intensity over 50% in form A. It is to be understood that a specified  $2\theta$  angle means the specified value  $\pm 0.2^\circ$ .

In another specific embodiment, 1:1 compound (I) fumarate form A is characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of  $112^\circ\text{C}$  and  $158^\circ\text{C}$ .

In another embodiment, 1:1 compound (I) fumarate is a single crystalline form, form B. In a specific embodiment, form B of 1:1 compound (I) fumarate is characterized by the X-ray powder diffraction pattern shown in Figure 8. In a more particular embodiment, 1:1 compound (I) fumarate form B is characterized by an X-ray powder diffraction pattern which comprises peaks at:

- a)  $11.9^{\circ}$  and  $14.9^{\circ} \pm 0.2$  in  $2\theta$  (major peaks); or
- b)  $11.9^{\circ}$ ,  $14.9^{\circ}$ ,  $18.7^{\circ}$ , and  $21.5^{\circ} \pm 0.2$  in  $2\theta$ ; or
- c)  $5.5^{\circ}$ ,  $5.9^{\circ}$ ,  $11.9^{\circ}$ ,  $14.9^{\circ}$ ,  $16.7^{\circ}$ ,  $17.4^{\circ}$ ,  $18.7^{\circ}$ ,  $21.5^{\circ}$ , and  $23.4^{\circ} \pm 0.2$  in  $2\theta$ .

The major peaks described herein have a relative intensity over 75% in form B.

In another specific embodiment, 1:1 compound (I) fumarate form B is characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of  $58^{\circ}\text{C}$  and  $162^{\circ}\text{C}$ .

In another embodiment, 1:1 compound (I) fumarate is a single crystalline form, form C. In a specific embodiment, 1:1 compound (I) fumarate form C is characterized by the X-ray powder diffraction pattern of the single crystalline shown in Figure 9. In a more particular embodiment, 1:1 compound (I) fumarate form C is characterized by an X-ray powder diffraction pattern which comprises peaks at:

- a)  $16.8^{\circ}$ ,  $16.9^{\circ}$ , and  $19.9^{\circ} \pm 0.2$  in  $2\theta$  (major peaks); or
- b)  $9.8^{\circ}$ ,  $16.8^{\circ}$ ,  $16.9^{\circ}$ ,  $19.9^{\circ}$ , and  $23.5^{\circ} \pm 0.2$  in  $2\theta$ ; or
- c)  $9.7^{\circ}$ ,  $9.8^{\circ}$ ,  $11.7^{\circ}$ ,  $15.1^{\circ}$ ,  $16.8^{\circ}$ ,  $16.9^{\circ}$ ,  $19.9^{\circ}$ ,  $23.5^{\circ}$ , and  $23.7^{\circ} \pm 0.2$  in  $2\theta$ .

The major peaks described herein have a relative intensity over 75% in form C.

In another specific embodiment, 1:1 compound (I) fumarate form C is characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of  $62^{\circ}\text{C}$  and  $156^{\circ}\text{C}$ .

In another embodiment, 1:1 compound (I) fumarate is a single crystalline form, form D. In a specific embodiment, Form D of 1:1 compound (I) fumarate is characterized by the X-ray powder diffraction pattern in Figure 10. In a more specific embodiment, the X-ray diffraction pattern of Form D comprises peaks at:

- a)  $9.6^{\circ}$ ,  $12.8^{\circ}$ ,  $16.0^{\circ}$ , and  $22.0^{\circ} \pm 0.2$  in  $2\theta$  (major peaks); or
- b)  $9.6^{\circ}$ ,  $12.8^{\circ}$ ,  $16.0^{\circ}$ ,  $16.9^{\circ}$ ,  $21.2^{\circ}$ , and  $22.0^{\circ} \pm 0.2$  in  $2\theta$ ; or
- c)  $9.6^{\circ}$ ,  $12.8^{\circ}$ ,  $16.0^{\circ}$ ,  $16.9^{\circ}$ ,  $20.8^{\circ}$ ,  $21.2^{\circ}$ ,  $21.5^{\circ}$ , and  $22.0^{\circ} \pm 0.2$  in  $2\theta$ .
- d)  $9.6^{\circ}$ ,  $11.7^{\circ}$ ,  $12.0^{\circ}$ ,  $12.8^{\circ}$ ,  $16.0^{\circ}$ ,  $16.6^{\circ}$ ,  $16.9^{\circ}$ ,  $18.1^{\circ}$ ,  $19.2^{\circ}$ ,  $19.8^{\circ}$ ,  $20.7^{\circ}$ ,  $20.8^{\circ}$ ,  $21.2^{\circ}$ ,  $21.5^{\circ}$ ,  $22.0^{\circ}$ ,  $22.5^{\circ}$ ,  $24.0^{\circ}$ ,  $26.0^{\circ}$ , and  $29.8^{\circ} \pm 0.2$  in  $2\theta$ .

The major peaks described herein have a relative intensity over 85% in form D.



In another specific embodiment, at least 90% by weight of the 1:1 compound (I) fumarate Form D is characterized by differential scanning calorimeter (DSC) peak phase transition temperature of 219°C.

In another embodiment, 1:1 compound (I) maleate is a single crystalline form, Form A. In a specific embodiment, form A of 1:1 compound (I) maleate is characterized by the X-ray powder diffraction pattern in Figure 11. In a more specific embodiment, form A of 1:1 compound (I) maleate is characterized by the X-ray powder diffraction pattern which comprises peaks at:

a) 11.5°, 12.6°, 14.9°, and 15.1° ± 0.2 in 2θ; or

b) 10.8°, 11.5°, 12.4°, 12.6°, 14.9°, 15.1°, and 17.1° ± 0.2 in 2θ; or

c) 5.8°, 10.8°, 11.5°, 12.4°, 12.6°, 14.9°, 15.1°, 17.1°, 18.6°, 23.5°, and 26.1° ± 0.2 in 2θ; or

d) 5.5°, 5.8°, 10.8°, 11.5°, 12.4°, 12.6°, 14.1°, 14.9°, 15.1°, 16.7°, 17.1°, 17.8°, 18.6°, 19.5°, 19.9°, 21.9°, 22.2°, 23.0°, 23.3°, 23.5°, 23.9°, and 26.1° ± 0.2 in 2θ.

The major peaks described herein have a relative intensity over 90% in form A.

In another specific embodiment, 1:1 compound (I) maleate form A is characterized by differential scanning calorimeter (DSC) peak phase transition temperature of 219°C.

The fumarate salt of compound (I) or the maleate salt of compound (I) described herein is either in an amorphous form or in a crystalline form. The fumarate salt of compound (I) or the maleate salt of compound (I) described in the present invention includes both an unsolvated form and a solvate form.

“Solvate form” refers to a solid or a crystalline form of the fumarate salt of compound (I) or the maleate salt of compound (I), where solvent is combined with the fumarate salt of compound (I) or the maleate salt of compound (I) in a definite ratio (*e.g.*, a molar ratio of 1:1 or 1:2) as an integral part of the solid or a crystal.

“Unsolvated form” refers to no definite ratio between a solvent molecule and the fumarate salt of compound (I) or the maleate salt of compound (I), and the solvent molecule is not substantially (*e.g.*, less than 10% by weight) existed in the fumarate salt of compound (I) or the maleate salt of compound (I). Well known solvent molecules include water, methanol, ethanol, n-propanol, and isopropanol.

In the present invention, form A of 1:1 compound (I) fumarate is an isopropanol solvate, which has a molar ratio of 2:1 between the compound (I) fumarate and isopropanol.

Form B-D of 1:1 compound (I) fumarate and form A of 1:1 compound (I) maleate described herein are not solvates, i.e., each are an unsolvated form.

*Methods of treatment using compound (I) fumarate and compound (I) maleate*

5 1:1 Compound (I) fumarate and 1:1 compound (I) maleate can inhibit various kinases, including PLK4. Thus, 1:1 compound (I) fumarate and 1:1 compound (I) maleate of the invention are useful in the treatment of diseases or conditions associated with such kinase. For example, PLK4 is believed to be involved in cellular mitotic progression. Thus, small molecule inhibitors of this enzyme can be potential anti-tumor agents.

10 In a specific embodiment, 1:1 compound (I) fumarate and 1:1 compound (I) maleate are PLK4 inhibitors, and are useful for treating diseases, such as cancer, associated with such a kinase.

Another aspect of the invention relates to a method of treating a subject with cancer, comprising administering to the subject an effective amount of 1:1 compound (I) fumarate  
15 and 1:1 compound (I) maleate. In one embodiment, 1:1 compound (I) fumarate and 1:1 compound (I) maleate inhibit the growth of a tumor. Specifically, 1:1 compound (I) fumarate and 1:1 compound (I) maleate inhibit the growth of a tumor that overexpresses PLK4. In another embodiment, 1:1 compound (I) fumarate and 1:1 compound (I) maleate inhibit the growth of the tumor by inducing apoptosis of the tumor cells or by inhibiting proliferation of  
20 the tumor cells.

Cancers that can be treated or prevented by the methods of the present invention include lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiform, ovarian cancer, lymphoma, leukemia, melanoma, sarcoma, paraneoplasia, osteosarcoma, germinoma, glioma and mesothelioma. In one  
25 specific embodiment, the cancer is lung cancer, breast cancer, colon cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, ovarian cancer, lymphoma, leukemia, osteosarcoma, germinoma, glioma, fibrosarcoma, gastrointestinal sarcoma, fibrous histiocytoma, round cell sarcoma, synovial sarcoma, cervical cancer, anogenital cancer, head and neck cancer, and oropharyngeal cancer. In one specific embodiment, the cancer is lung  
30 cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme or ovarian cancer. In another specific embodiment, the cancer is lung cancer, breast cancer, colon cancer, brain cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiform or ovarian cancer. In another specific embodiment, the cancer is lung cancer, breast cancer, and colon cancer. In yet another specific embodiment, the cancer

is a breast cancer. In yet another specific embodiment, the cancer is a basal sub-type breast cancer or a luminal B sub-type breast cancer. In one embodiment, the basal sub-type breast cancer is ER (estrogen receptor), HER2 and PR (progesterone receptor) negative breast cancer. In yet another specific embodiment, the cancer is a soft tissue cancer. A “soft tissue cancer” is an art-recognized term that encompasses tumors derived from any soft tissue of the body. Such soft tissue connects, supports, or surrounds various structures and organs of the body, including, but not limited to, smooth muscle, skeletal muscle, tendons, fibrous tissues, fatty tissue, blood and lymph vessels, perivascular tissue, nerves, mesenchymal cells and synovial tissues. Thus, soft tissue cancers can be of fat tissue, muscle tissue, nerve tissue, joint tissue, blood vessels, lymph vessels, and fibrous tissues. Soft tissue cancers can be benign or malignant. Generally, malignant soft tissue cancers are referred to as sarcomas, or soft tissue sarcomas. There are many types of soft tissue tumors, including lipoma, lipoblastoma, hibernoma, liposarcoma, leiomyoma, leiomyosarcoma, rhabdomyoma, rhabdomyosarcoma, neurofibroma, schwannoma (neurilemoma), neuroma, malignant schwannoma, neurofibrosarcoma, neurogenic sarcoma, nodular tenosynovitis, synovial sarcoma, hemangioma, glomus tumor, hemangiopericytoma, hemangioendothelioma, angiosarcoma, Kaposi sarcoma, lymphangioma, fibroma, elastofibroma, superficial fibromatosis, fibrous histiocytoma, fibrosarcoma, fibromatosis, dermatofibrosarcoma protuberans (DFSP), malignant fibrous histiocytoma (MFH), myxoma, granular cell tumor, malignant mesenchymomas, alveolar soft-part sarcoma, epithelioid sarcoma, clear cell sarcoma, and desmoplastic small cell tumor. In a particular embodiment, the soft tissue cancer is a sarcoma selected from the group consisting of a fibrosarcoma, a gastrointestinal sarcoma, a leiomyosarcoma, a dedifferentiated liposarcoma, a pleomorphic liposarcoma, a malignant fibrous histiocytoma, a round cell sarcoma, and a synovial sarcoma.

The invention further relates to a method of treating a subject with tumor cells, comprising administering to the subject, an amount of a compound disclosed herein that is effective to reduce effectively PLK4 activity in the subject.

The term an “effective amount” means an amount when administered to the subject which results in beneficial or desired results, including clinical results, e.g., inhibits, suppresses or reduces the cancer (e.g., as determined by clinical symptoms or the amount of cancer cells) in a subject as compared to a control.

As used herein, “treating a subject with a cancer” includes achieving, partially or substantially, one or more of the following: arresting the growth of a cancer, reducing the extent of a cancer (e.g., reducing size of a tumor), inhibiting the growth rate of a cancer,

ameliorating or improving a clinical symptom or indicator associated with the cancer (such as tissue or serum components) or increasing longevity of the subject; and reducing the likelihood of recurrence of the cancer.

As used herein, the term “reducing the likelihood of recurrence of a cancer” means  
5 inhibiting or delaying the return of a cancer at or near a primary site and/or at a secondary site after a period of remission. It also means that the cancer is less likely to return with treatment described herein than in its absence.

As used herein, the term “remission” refers to a state of cancer, wherein the clinical symptoms or indicators associated with a cancer have disappeared or cannot be detected,  
10 typically after the subject has been successfully treated with an anti-cancer therapy.

Generally, an effective amount of a compound of the invention varies depending upon various factors, such as the given drug or compound, the pharmaceutical formulation, the route of administration, the type of disease or disorder, the identity of the subject or host being treated, and the like, but can nevertheless be routinely determined by one skilled in the  
15 art. An effective amount of a compound of the present invention may be readily determined by one of ordinary skill by routine methods known in the art.

In an embodiment, an effective amount of 1:1 compound (I) fumarate and 1:1 compound (I) maleate ranges from about 0.01 to about 1000 mg/kg body weight, alternatively about 0.05 to about 500 mg/kg body weight, alternatively about 0.1 to about 100  
20 mg/kg body weight, alternatively about 0.1 to about 15 mg/kg body weight, alternatively about 1 to about 5 mg/kg body weight, and in another alternative, from about 2 to about 3 mg/kg body weight. The skilled artisan will appreciate that certain factors may influence the dosage required to effectively treat a subject suffering from cancer and these factors include, but are not limited to, the severity of the disease or disorder, previous treatments, the general  
25 health and/or age of the subject and other diseases present.

Moreover, a “treatment” regime of a subject with an effective amount of the compound of the present invention may consist of a single administration, or alternatively comprise a series of applications. For example, 1:1 compound (I) fumarate and 1:1 compound (I) maleate may be administered at least once a week. However, in another  
30 embodiment, the compound may be administered to the subject from about one time per week to once daily for a given treatment. The length of the treatment period depends on a variety of factors, such as the severity of the disease, the age of the patient, the concentration and the activity of the compounds of the present invention, or a combination thereof. It will also be appreciated that the effective dosage of the compound used for the treatment or

prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some instances, chronic administration may be required.

5 A "subject" is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, e.g., companion animals (e.g., dogs, cats, and the like), farm animals (e.g., cows, sheep, pigs, horses, and the like) and laboratory animals (e.g., rats, mice, guinea pigs, and the like).

10 The compounds of the invention can be administered to a patient in a variety of forms depending on the selected route of administration, as will be understood by those skilled in the art. The compounds of the invention may be administered, for example, by oral, parenteral, buccal, sublingual, nasal, rectal, patch, pump or transdermal administration and the pharmaceutical compositions formulated accordingly. Parenteral administration includes intravenous, intraperitoneal, subcutaneous, intramuscular, transepithelial, nasal, intrapulmonary, intrathecal, rectal and topical modes of administration. Parenteral  
15 administration can be by continuous infusion over a selected period of time.

*Pharmaceutical compositions including 1:1 compound (I) fumarate and 1:1 compound (I) maleate*

20 1:1 Compound (I) fumarate or 1:1 compound (I) maleate or any one or more of the crystal forms disclosed herein can be suitably formulated into pharmaceutical compositions for administration to a subject.

In one embodiment, the present invention provides a pharmaceutical composition comprising 1:1 Compound (I) fumarate or 1:1 compound (I) maleate as described above, and a pharmaceutically acceptable carrier or diluent, wherein at least 80% (preferably 90%, more  
25 preferably 99%) by weight of the salt is crystalline.

The pharmaceutical compositions of the present teachings optionally include one or more pharmaceutically acceptable carriers and/or diluents therefor, such as lactose, starch, cellulose and dextrose. Other excipients, such as flavoring agents; sweeteners; and preservatives, such as methyl, ethyl, propyl and butyl parabens, can also be included. More  
30 complete listings of suitable excipients can be found in the Handbook of Pharmaceutical Excipients (5<sup>th</sup> Ed., Pharmaceutical Press (2005)). A person skilled in the art would know how to prepare formulations suitable for various types of administration routes. Conventional procedures and ingredients for the selection and preparation of suitable formulations are described, for example, in Remington's Pharmaceutical Sciences (2003 -

20th edition) and in The United States Pharmacopeia: The National Formulary (USP 24 NF19) published in 1999. The carriers, diluents and/or excipients are “acceptable” in the sense of being compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.

5           Typically, for oral therapeutic administration, a compound of the present teachings may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.

          Typically for parenteral administration, solutions of a compound of the present teachings can generally be prepared in water suitably mixed with a surfactant such as  
10   hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, DMSO and mixtures thereof with or without alcohol, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.

          Typically, for injectable use, sterile aqueous solutions or dispersion of, and sterile  
15   powders of, a compound described herein for the extemporaneous preparation of sterile injectable solutions or dispersions are appropriate.

          For nasal administration, the compounds of the present teachings can be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a physiologically acceptable aqueous or non-aqueous  
20   solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomizing device. Alternatively, the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal after use. Where the dosage form comprises an aerosol dispenser, it will contain a  
25   propellant which can be a compressed gas such as compressed air or an organic propellant such as fluorochlorohydrocarbon. The aerosol dosage forms can also take the form of a pump-atomizer.

          For buccal or sublingual administration, the compounds of the present teachings can be formulated with a carrier such as sugar, acacia, tragacanth, or gelatin and glycerine, as  
30   tablets, lozenges or pastilles.

          For rectal administration, the compounds described herein can be formulated in the form of suppositories containing a conventional suppository base such as cocoa butter.

          The invention is illustrated by the following examples, which are not intended to be limiting in any way.

## EXPERIMENTAL

**Abbreviations:**

	BSA	benzene sulfonic acid
	d	days
5	EtOAc	ethyl acetate
	EtOH	ethanol
	h	hours
	HPLC	high performance liquid chromatography
	IPA	isopropanol
10	IBAc	isobutyl acetate
	MeOH	methanol
	MIBK	methyl isobutyl ketone
	min	minutes
	MTBE	methyl tert-butylether
15	NMR	nuclear magnetic resonance
	pTSA	para toluenesulfonic acid
	RBF	round bottom flask
	RH	relative humidity
	Rel. Int.	relative intensity
20	rt	room temperature
	temp	temperature
	TGA	thermogravimetric analysis
	THF	tetrahydrofuran
	wt%	percent by weight
25	XRPD	X-ray powder diffraction

**Analysis Conditions****Differential Scanning Calorimetry Analysis (DSC)**

DSC analyses were carried out on a Mettler 822e differential scanning calorimeter or  
30 a TA instruments Q2000. Samples were weighed in an aluminum pan, covered with a pierced  
lid, and then crimped. Analysis conditions were 30-120, 30-200, 30-300 °C and 40-300 °C  
ramped at 10 °C/min.

**Thermal Gravimetric Analysis (TGA)**

TGA analyses were carried out on a Mettler 851e SDTA thermogravimetric analyzer. Samples were weighed in an alumina crucible and analyzed from 30-230, 30-300 and 30-350 °C and at a ramp rate of 10 °C/min.

**5 X-Ray Powder Diffraction (XRPD)**

Samples were analyzed on a Panalytical CubiX-Pro X-ray powder diffractometer or a Bruker AXS/Siemens D5000 diffractometer.

10 Panalytical Conditions: Samples were placed on a silicon zero-return ultra-micro sample holder. The samples were irradiated with copper K-alpha X-rays with the X-ray tube operated at 40 kV/30 mA. The samples were scanned in continuous mode along the range 3 to 45°.

Bruker AXS/Siemens D5000 Conditions: A high-power Cu-target was used operating at 50kV/35mA. The secondary beam was monochromatized by a solid state Kevex detector. The samples were scanned along the range 2 – 35° (2σ) where representative peaks for most  
15 of the organic crystalline compounds occur.

**Gravimetric Moisture Sorption**

Gravimetric moisture sorption experiments were carried out on a Hiden dynamic vapour sorption analyzer by first holding the sample at 40% RH and 25 °C until an equilibrium weight was reached or for a maximum of four hours. The sample was then  
20 subjected to an isothermal (25 °C) adsorption scan from 40 to 90% RH in steps of 10%. The sample was allowed to equilibrate to an asymptotic weight at each point for a maximum of four hours. Following adsorption, a desorption scan from 85 to 5% RH (at 25 °C) was run in steps of –10% again allowing a maximum of four hours for equilibration to an asymptotic weight. An adsorption scan was then performed from 0% RH to 40% RH in steps of  
25 +10%RH.

**Raman Spectroscopy**

Samples for Raman analysis were analyzed on a Kaiser RXN1 Macroscope with PhAT Probe. Solids obtained from the 96 well plate crystallizations were analyzed using the following conditions:

30 Raman Source: 785 nm laser  
Microscope Objective 1.2 mm  
Single Exposure Time: 12 sec  
Co-additions: 12



Enabled Exposure options: Cosmic Ray filtering, Dark Subtraction, Intensity Calibration

### Optical Microscopy

5 Samples were examined with a Leica DMRB polarized light microscope combined with a digital camera ( $1600 \times 1200$  resolution). Small amounts of samples were dispersed in mineral oil on a glass slide with cover slips and viewed with 100x magnification or higher.

### Birefringence

10 Samples for Birefringence analysis were analyzed on a Coleman Technologies birefringence imager. Solids obtained from the 96 well plate crystallizations were analyzed using the following conditions:

Lighting: 37

Exposure: 57.9

Polarization: 0.0

Well mask diameter: 6.2

15 Target Intensity: 80

Target Percentile: 90.0

Maximum Mean Intensity: 100

### Nuclear Magnetic Resonance

20 Samples for Proton NMR were analyzed using a Bruker 400 MHz spectrometer.

### Example 1: Combinatorial Salt Screen

A salt screen was performed using six solvents (IPA, THF, acetone, acetonitrile, EtOH and EtOAc) and twenty-eight pharmaceutically acceptable acids (HCl, HBr,  $H_3PO_4$ ,  $H_2SO_4$ ,  $CH_3SO_3H$ , pTSA, BSA, naphthalene sulfonic acid, ethane sulfonic acid, methane sulfonic acid, adipic acid, ethane disulfonic acid, maleic acid, benzoic acid, L-malic acid, citric acid, L-lactic acid, hippuric acid, L-pyroglutamic acid, succinic acid, L-tartaric acid, formic acid, fumaric acid, glutaric acid, L-ascorbic acid, sorbic acid, benzoic acid, and malonic acid). A 96-well plate was charged with 200  $\mu$ L of a 20 mg/mL solution of compound (I) in MeOH in each well. The solvent was then evaporated under a flow of nitrogen, leaving approximately 4 mg of the starting material in each well. The primary solvent of interest was then added to each well (500  $\mu$ L). The plates were heated to 50 °C and stirred magnetically for 10 min to ensure complete dissolution of A. Each well was then charged with the designated counterion solution at a volume corresponding to 1.05 equivalents of each acid and allowed to equilibrate at temperature for 10 min. The plates

were then cooled at 20 °C/h to 25 °C, at which point the master plate was daughtered by transferring 200 µL from each well into an evaporation plate. The plates were then cooled to ambient temperature, stored overnight at 5 °C and checked for the presence of solids. The solvent from the master plates was then removed by wicking with sorbent paper. The master and evaporation plates were then dried under nitrogen overnight. Wells that contained solid material were then scored and ranked for birefringence, unique Raman spectrum and threshold solubility. Suitable solvent and counterion combinations were then reevaluated for salt formation with A at an increased scale.

## 10 **Example 2: Intermediate Scale Salt Formation**

Approximately 40 mg of compound (I), was weighed into an 8 mL vial containing a magnetic stir bar. To the vial, primary solvent was added to ensure dissolution at elevated temperature. Following dissolution, 1.05 equivalents of acid was added dropwise as a 0.125, 0.25 or 0.5 M solution. All mixtures were allowed to stir at elevated temperature for 15 min, followed by cooling to room temperature at a rate of 10 °C/h and stirring overnight. Samples that did not exhibit precipitation after cooling were scratched with a spatula to induce nucleation and stored in a freezer at -10 to -20 °C. The vials were inspected for crystal growth after 1 h. Samples from conditions that afforded solids were centrifuged, filtered or evaporated under nitrogen. All other samples were allowed to equilibrate at -20°C for 72 h. Vials that did not show precipitation were then dried under nitrogen. The resulting solids were then slurried with IPA for 5 d. From these experiments, only amorphous solids were identified for all counterions except for the fumaric acid salt. Unique polymorphic forms of the fumarate salt of compound (I) are described below.

## 25 **Preparation of Crystalline Salts of Compound (I)**

### **Example 3: Preparation of Form A of 1:1 compound (I) fumarate**

Compound (I) (42 mg, 0.078 mmol) was dissolved into acetonitrile (0.5 mL) and heated to 50 °C. Fumaric acid (0.33 mL of 0.25M solution in IPA) was added and the mixture stirred for 15 min. The precipitate was filtered and determined to be amorphous due to lack of observable birefringence. The amorphous solid was then slurried with IPA (0.5 mL) for 5 d. The solid obtained from the slurry showed birefringence and was further characterized as an IPA solvate by XRPD, DSC, <sup>1</sup>H NMR and TGA and denoted fumarate form A.

Table 1. XRPD of Fumarate Form A

2θ angle	Rel. Int.(%)
8.17	43%
9.69	100%
10.69	33%
11.51	30%
13.63	25%
14.89	36%
16.73	61%
18.09	27%
18.83	23%
20.05	50%
23.49	34%
24.45	26%

**Example 4: Preparation of Form B of 1:1 compound (I) fumarate**

Desolvation of fumarate form A by vacuum drying at 60 °C for 2 d resulted in a crystalline material with a DSC thermogram and XRPD designated as form B. Form B can also be prepared directly by dissolving the amorphous monofumarate salt in EtOAc and seeding with form B crystals. Gravimetric moisture sorption indicates that the salt form is hygroscopic and forms a tetrahydrate at 90%RH.

Table 2. XRPD of Fumarate Form B

2θ angle	Rel. Int.(%)
5.51	39.5
5.91	38.7
11.91	100.0
14.93	83.5
16.71	40.2
17.35	40.4
18.73	42.8
21.53	41.0
23.41	43.3

**Example 5: Preparation of Form C of 1:1 Compound (I) fumarate**

A third fumarate polymorph can be obtained by dissolution of amorphous fumarate salt into THF and seeding with fumarate form B crystals. The solvent was slowly evaporated to a white solid which exhibited a XRPD pattern and Raman spectrum different from form B and was designated as fumarate form C.

Table 3. XRPD of Fumarate Form C

2 $\theta$ angle	Rel. Int.(%)
9.71	68.1
9.83	70.2
11.71	59.5
15.05	60.1
16.83	88.7
16.87	84.7
19.93	100.0
23.45	70.7
23.65	69.6

**Example 6: Preparation of Form D of 1:1 Compound (I) fumarate**

Slurrying fumarate form C with acetonitrile for 10 d at rt resulted in transition to a new crystal form, denoted form D, which showed a distinct Raman Spectrum and XRPD pattern. The phase transition by DSC was much higher than the other forms and shows the highest stability of the four polymorphs identified. Form D can be directly prepared as follows: A 250-mL three neck RBF equipped with a stir bar was charged with compound (I) (6.01 g, 11 mmol) and fumaric acid (1.41 g, 12 mmol). Acetone (50 mL) was added and the slurry was heated to 50 °C until the solution became clear. Precipitation was observed after 10 min, and stirring was continued for an additional 30 min. MTBE (25 mL) was added and the solution was cooled to rt and stirred overnight. The solids were filtered and dried under vacuum at 60 °C for 2 d to give the title compound (I) as a white solid (6.65 g, 91%).

<sup>1</sup>H NMR (400 MHz, CD<sub>3</sub>OD)  $\delta$  8.00 (d, J = 8.4 Hz, 1H), 7.68 (d, J = 8.0 Hz, 2H), 7.50-7.45 (m, 5H), 7.03 (d, J = 8.1 Hz, 1H), 6.83 (d, J = 8.4 Hz, 1H), 6.73 (s, 2H), 6.60 (dd, J = 8.4, 2.5 Hz, 1H), 5.58 (s, 1H), 4.00 (s, 2H), 3.82-3.78 (m, 2H), 3.36 (t, J = 8.4 Hz, 1H), 3.26 (s, 3H), 3.13-3.10 (m, 2H), 2.34 (t, J = 11.4 Hz, 2H), 2.25-2.16 (m, 2H), 1.01 (d, J = 6.0 Hz, 6H).

Table 4. XRPD of Form D

2 $\theta$ angle	Rel. Int.(%)
9.59	97.3
11.69	39.2
12.03	53.4
12.83	100.0
15.95	92.6

2 $\theta$ angle	Rel. Int.(%)
16.55	47.2
16.93	73.3
18.13	47.8
19.23	59.0
19.81	55.4
20.67	59.1
20.79	61.9
21.23	71.5
21.49	66.6
21.97	97.2
22.53	42.1
23.97	53.9
24.03	46.2
26.03	32.5
29.75	41.6

The fumaric acid salt can be generated as form D under various conditions. The crystal form can be generated through seeding with crystals of form B or D as shown in Table 5. The salt can be crystallized directly by dissolving the parent compound (I) in polar solvents such as ethyl acetate, acetone or ethanol and delivering fumaric acid in polar solvents such as methanol, ethanol, THF and isopropanol, as shown in Table 6. Yields are generally improved when an antisolvent, such as MTBE, is added. Conditions that do not give form D include when the compound (I) is dissolved into less polar solvents such as acetonitrile, 2-methyltetrahydrofuran and methylisobutyl ketone. Also, addition of hexane as an antisolvent does not promote crystal form D.

The preferred Form D can also be generated by dissolving compound (I) into an appropriate solvent, such as methanol, ethanol, THF or acetone and delivering fumaric acid directly as a solid, as seen in Table 7. Yields are improved when an antisolvent such as MTBE or IBAC is added. Form D is not formed by this method when the primary solvent is less polar, as is the case with ethyl acetate and MTBE.

A 2:1 compound (I)/fumaric acid crystalline salt could not be generated. Two equivalents of compound (I) was dissolved into a primary solvent such as EtOAc, EtOH, THF, IPA and one equivalent of fumaric acid was added as a solid, or in a solution with IPA or EtOH. The resultant solutions were heated to 50°C for 30 min and cooled to rt. MTBE was added and the mixture was slurried for 24 h. Characterization of both the solid and filtrate by <sup>1</sup>H NMR revealed only 1:1 compound (I)/ fumarate salt was obtained.

Table 5. Crystallization of fumarate salt with seeding

Primary Solvent	Delivery Solvent	Equivalents	Temp (°C)	Seed addition	Yield (%)	Form
EtOAc	EtOH	1.05	50	B	77	D
EtOAc	EtOH	1.05	50	D	67	D

Table 6. Crystallization of fumarate salt

Primary Solvent	Delivery Solvent	Equivalents	Temp (°C)	Antisolvent	Yield (%)	Form
EtOAc	MeOH	1.05	50	MTBE	54	D
EtOAc	EtOH	1.05	50	MTBE	51	D
EtOAc	THF	1.05	50	MTBE	53	D
EtOAc	IPA	1.05	50	MTBE	50	D
EtOAc	THF	1.05	50	Hexane	-	-
2-MeTHF	MeOH	1.05	50	MTBE	-	-
2-MeTHF	EtOH	1.05	50	MTBE	-	-
2-MeTHF	THF	1.05	50	MTBE	-	-
Acetone	MeOH	1.05	50	MTBE	75	D
Acetone	EtOH	1.05	50	No	40	D
Acetone	THF	1.05	50	MTBE	72	D
Acetone	THF	1.05	50	Hexane	-	-
MIBK	THF	1.05	50	MTBE	-	-
EtOH	THF	1.05	50	MTBE	69	D
EtOH	THF	1.05	50	Hexane	-	-
THF	THF	1.05	50	Hexane	-	-

Table 7. Crystallization with fumaric acid added as solid

Primary Solvent	Equivalents	Temp (°C)	Antisolvent	Yield (%)	Form
MeOH	1.01	50	No	43	D
EtOH	1.14	50	No	61	D
EtOH	1.05	50	MTBE	74	D
EtOH	1.05	50	IBAc	74	D
THF	1.01	50	MTBE	64	D
Acetone	0.99	50	No	53	D
Acetone	1.05	50	MTBE	82	D
Acetone	1.05	50	IBAc	81	D
EtOAc	1.01	50	No	-	-
MTBE	1.01	50	No	-	-

### Rescoring of the Combinatorial Salt Screen Results

From the initial combinatorial process, only the fumarate salt was identified as crystalline. The results from the high throughput screen were reevaluated and new scores were generated that were independent of the solvent for each counterion. This rescoring proceeded for the different salts by combining the previous scores (visual inspection of solid formation, birefringence, uniqueness by Raman spectrum and threshold solubility) over all the solvents and summing them up for both the master and evaporation plates.

The two highest rescored acids, maleic and methane sulfonic acid, were further evaluated under additional solvent and antisolvent conditions. Salts obtained from methane sulfonic acid exhibited hygroscopicity. However, a crystalline salt with maleic acid was identified. The preparation and characterization of a maleate salt of compound A is described below.

### Example 7: Preparation of Form A of 1:1 Compound (I) maleate

A 250-mL three neck round bottom flask equipped with a stir bar was charged with compound (I) (4.96 g, 9.3 mmol). Acetone (55 mL) was added and heated to 50 °C. Maleic acid (20 mL of 0.5 M solution in acetone) was added resulting in a clear solution which became turbid after 1 min. The solution was cooled to rt and stirred for 24 h as a thick slurry.

The solids were filtered, washed with MTBE and dried for 30 h at 60 °C under vacuum to give a white solid (5.52 g, 91%). The salt was characterized as a crystalline by XRPD and denoted form A.

<sup>1</sup>H NMR (*CD*<sub>3</sub>*OD*) δ: 8.04 (d, *J* = 8.5 Hz, 1H), 7.77 (d, *J* = 8.0 Hz, 2H), 7.45 - 7.61 (m, 5H), 7.07 (d, *J* = 8.8 Hz, 1H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.62 (dd, *J* = 8.5, 2.5 Hz, 1H), 6.27 (s, 2H), 5.59 (d, *J* = 2.5 Hz, 1H), 4.30 (s, 2H), 3.86-3.82 (m, 2H), 3.34-3.43 (m, 2H), 3.27 (s, 3H), 2.74-2.68 (m, 2H), 2.32-2.10 (m, 2H), 1.23 (d, *J* = 6.3 Hz, 6H).

Table 8. XRPD of Maleate Form A

2 $\theta$ angle	rel. intensity
5.45	28.2
5.75	54.4
10.83	70.9
11.49	111.9
12.37	79.3
12.59	103.2
14.05	38.1
14.91	96.1
15.07	100.0
16.73	29.6
17.05	75.9
17.83	20.6
18.55	51.7
19.51	34.8
19.91	30.7
21.89	25.9
22.15	34.6
23.03	39.4
23.31	45.3
23.51	56.1
23.89	33.3
26.09	60.3

Maleate form A can be generated from a polar solvent, such as EtOH, acetone, isopropyl acetate, ethyl acetate, isopropanol or THF with or without addition of a non-polar  
5 antisolvent, such as MTBE. A 2:1 compound (I)/maleic acid crystalline salt could not be generated.

#### Preparation of Amorphous salts of Compound (I)

##### Example 8: Preparation of HCl salt of compound (I)

10 Compound (I) (6.7 g, 12.5 mmol) was dissolved into THF (25 mL) and 1M HCl in ether (13.8 mL, 13.8 mmol) was added at rt and the solution diluted with ether (200 mL). The mixture was stored at rt for 1h, and the resulting solid was filtered. The solid forms a gel upon standing and was dissolved into water (100 mL) and freeze dried to a yellow powder (5.8 g, 81%).



<sup>1</sup>H NMR (400 MHz, *CD*<sub>3</sub>*OD*) δ 7.75 (d, *J* = 8.4 Hz, 1H), 7.57 (d, *J* = 8.0 Hz, 2H), 7.46 (d, *J* = 8.0 Hz, 2H), 7.42 (s, 1H), 7.35 (d, *J* = 16.8 Hz, 1H), 7.30 (d, *J* = 16.4 Hz, 1H), 6.82 (d, *J* = 9.2 Hz, 1H), 6.80 (d, *J* = 8.8 Hz, 1H), 6.51 (d, *J* = 8.4 Hz, 1H), 5.19 (s, 1H), 4.28 (s, 2H), 3.92-3.80 (m, 2H), 3.40-3.30 (m, 2H), 3.27 (t, *J* = 8.4 Hz, 1H), 3.15 (s, 3H), 2.70 (t, *J* = 11.4 Hz, 2H), 2.15-2.05 (m, 2H), 1.18 (d, *J* = 6.0 Hz, 6H).

#### Example 9: Preparation of phosphate salt of compound (I)

Compound (I) (148 mg, 0.27 mmol) was dissolved into EtOAc (0.5 mL) and 0.5M phosphoric acid in EtOAc (0.58 mL, 0.28 mmol) was added at 50 °C and the solution was stirred for 15 min and cooled to rt. The solids were filtered and dried for 4 d at 60 °C to give the title compound (I) as a white solid (149 mg, 85%).

<sup>1</sup>H NMR (*CD*<sub>3</sub>*OD*) δ 8.00 (d, *J* = 8.5 Hz, 1H), 7.72 (d, *J* = 8.2 Hz, 2H), 7.49-7.58 (m, 5H), 7.04 (d, *J* = 8.0 Hz, 1H), 6.84 (d, *J* = 8.5 Hz, 1H), 6.61 (dd, *J* = 8.5, 2.5 Hz, 1H), 5.58 (d, *J* = 2.5 Hz, 1H), 4.21 (s, 2H), 3.97-3.89 (m, 2H), 3.34 - 3.39 (m, 1H), 3.26 (s, 3H), 2.55 (t, *J* = 11.8 Hz, 2H), 2.16-2.26 (m, 2H), 1.19 (d, *J* = 6.0 Hz, 6H).

#### Solubility Test and Pharmacokinetic Analyses

##### Methods:

A single oral dose in solution and as powder in capsule of the HCl salt of (I), fumarate form D and maleate form A were administered to female Sprague-Dawley rats at 5 mg/kg. Blood samples were collected in the presence of lithium heparin, and were centrifuged to generate plasma. The plasma was then analyzed for compound (I) plasma levels by LC/MS.

##### Preparation of test article for capsule dosing in rats:

All animals involved in the dosing schedule were weighed and assigned numbers. All capsules (Size 9 porcine hard gelatin capsules, Torpac) corresponding with each animal to be dosed were carefully numbered with a fine tip Sharpie. A small plastic weighing dish was placed on the scale, with one capsule lid placed on the dish and the base of the capsule loader with the other part of the capsule was loaded in the reservoir. The balance was tared. A funnel was placed on top of the capsule loading apparatus and the total mass was carefully noted. A piece of 4"x4" wax paper was folded in half creating a crease down the median. A small amount of finely ground compound (Ground the compound if required using mortar and pestle) was deposited in the crease of the wax paper and refolded. The folded wax paper was gently angled over the capsule loader funnel apparatus. A fine scapula was used to tease

an amount of compound powder out of the crease onto the funnel allowing it to trickle into the loading bay and ultimately the capsule. The difference in mass from the total mass was noted. The capsule loading funnel was removed and the balance door closed to ascertain the absolute weight of compound inside the capsule. The funnel was returned to the capsule loading apparatus and loading continued until the desired amount of drug was inside the capsule. Note: When adding minute quantities to the capsule, simply brushed fine powdered drug that settled on the funnel into the loading column. The funnel was removed and the weight was recorded. Calculated the amount of actual drug by multiplying weighed material by the bioequivalence ratio. The amount of actual drug was recorded. The capsule lid on the weighing dish was used to close the capsule tightly until it clicked into place.

All animals (n= 3/group) were dosed orally in a volume of 5 mL/kg. Following dosing, each rat was bled at each of the designated time points. For control animals, blood was collected by the same procedure. Blood was collected from the lateral saphenous vein. Blood aliquots (~50 µL) were collected in tubes coated with lithium heparin, mixed gently, then kept on ice and centrifuged at 2,500 xg for 15 minutes at RT, within 1 hour of collection. The plasma layer was collected, kept on ice and finally maintained frozen at -80 °C until further processing.

#### **Bioanalytical Methods**

Bioanalytical quantitation using HPLC/tandem quadrupole mass spectrometry (HPLC-MS) was performed. Plasma concentrations and  $T_{1/2}$  were calculated and reported.

##### *Plasma Assay:*

A 5 mg/mL standard solution in DMSO was diluted 100 fold and subsequently serially diluted in 50% DMSO. Aliquots (2 µL) of the serial dilutions were mixed with 18 µL of control plasma (20 µL total) for use as a standard curve. Plasma samples (20 µL) and standard samples were then diluted 5x with ice cold acetonitrile containing 100 ng/mL verapamil as internal standard (80% (v/v) acetonitrile). Acetonitrile precipitated samples and standards were filtered through 0.22 µm membranes in a 96-well format. Filtrates were then diluted with water to 30% acetonitrile.

##### *Dose Assay:*

Dosing solution (100 µL) was diluted with DMSO (900 µL) to ensure sample homogeneity. Dilution of the resulting solution into 30% acetonitrile (containing internal standard) was then performed in triplicate to bring the nominal concentration to less than 500 ng/mL, appropriate for LC-MS analysis. Serial dilution from a 5 mg/mL DMSO stock, into

30% acetonitrile (containing internal standard) provided a suitable standard curve. Samples and standards (10  $\mu$ L) were injected into the LC-MS system, as described below.

Concentrations of dose solutions were reported in mg/mL.

*LC-MS analysis:*

- 5 LC: 10  $\mu$ L of each sample and standard were injected onto a Waters Acquity CSH 1.7  $\mu$ m 2.1x100 mm column at 0.6 mL/min by an Acquity UPLC. The C18 column was equilibrated at 10% acetonitrile. Compounds were eluted with a gradient to 99% acetonitrile. All mobile phases contained 0.1% (v/v) formic acid.

Chromatographic elution:

t (min)	% B
0	5
0.75	5
1	20
4.5	99.9
5	99.9
5.4	5
6	5

10

MS: Column eluent was analyzed by electrospray ionization into a tandem quadrupole mass spec system (Waters Xevo TQ). Eluent composition was analyzed for three ion-pairs specific for the internal standard and three ion-pairs specific for the analyte.

#### Pharmacokinetic Analyses

- 15 Experimental samples were compared with standard curve samples to determine compound concentrations. Average compound concentrations (in  $\mu$ g/mL +/- standard deviation) were reported for each time-point. Limit of Detection (LLOQ) was reported as the lowest standard curve sample demonstrating a deviation of less than 20% of nominal concentration. PK analysis was performed by the Excel plugin PKfit;  $C_{\max}$  were determined  
 20 as the maximum average concentration observed at a given time point; the area under the curve (AUC) was reported for  $t_0$  to  $t_{\text{last}}$  hours. Plasma half-lives were reported when a minimum of 3 terminal time-points demonstrated first order elimination with an  $r^2 > 0.8$ .

- As shown in Table 9, crystalline salts of compound (I) were shown to be less soluble in deionized water compared to the amorphous phosphate and HCl salts. In many reported  
 25 cases, the increased solubility of the amorphous salts results in an increase in plasma concentrations relative to a more stable crystalline form (Hancock and Parks (2000) Pharm. Res. 17: 397-404; Pudipeddi and Serajuddin (2005) J. Pharm. Sci. 94: 929-39). However, when the plasma concentration-time profiles and pharmacokinetic parameters of amorphous

and crystalline salts were compared following oral dosing as powder in capsule (PIC) to female Sprague-Dawley rats, the difference in pharmacokinetic parameters was minimal (Table 10).

Table 9: Characterization summary of compound (I) Salts

Counterion	XRPD	Compound (D):acid ratio	DSC (°C)	TGA Loss (wt %)	Gravimetric Moisture Sorption	Solubility in DI water (µg/mL)
Fumarate	A	1.0:0.9	112, 158	7.2 (45-160 °C)		
Fumarate	B	1.0:1.0	58, 162	2.6 (40-120 °C)	3.7 wt% 60%RH 10.5 wt% 90%RH	
Fumarate	C	1.0:1.1	62, 156	2.6 (30-100 °C)		625
Fumarate	D	1.0:1.0	219	0.9 (30-100°C)	2.1 wt% 60%RH 4.0 wt% 90%RH	170
Maleate	A	1.0:0.95	219	No loss observed until melt	1.3 wt%, 60%RH 2.2 wt%, 90%RH	
Phosphate	Amorphous	1.0:1.1	83, 179	1.9	6.1 wt% 60%RH 10.9 wt% 90%RH	$\geq 1 \times 10^5$
HCl	Amorphous			2.3 (30-150 °C)		$\geq 1 \times 10^5$


Table 10: Pharmacokinetic Parameters after PO Administration of compound (I) Salts, Powder in Capsule, to Sprague-Dawley Rats

Salt form	HCl	Fumarate (form D)	Maleate (form A)
Oral Dose (mg/kg)	5.0	5.0	5.0
C <sub>max</sub> (ng/mL)	250	270	200
AUC <sub>0-last</sub> (ng.h/mL)	2400	2780	1500

## CLAIMS

What is claimed is:

1. A fumarate salt of compound (I) represented by the following structural formula:




Compound (I)

- 5 wherein the molar ratio between compound (I) and fumaric acid is 1:1.
2. The fumarate salt of claim 1, wherein at least 80% by weight of the salt is crystalline.
3. The fumarate salt of claim 1 or 2, wherein at least 80% by weight of the salt is in a single crystalline form.
4. The fumarate salt of any one of claims 1-3, wherein at least 99% by weight of the salt is crystalline.
- 10 is crystalline.
5. The fumarate salt of any one of claims 1-4, wherein at least 99% by weight of the salt is in a single crystalline form.
6. The fumarate salt of any one of claims 1-5, wherein at least 90% by weight of the fumarate salt is single crystalline form A, and the X-ray powder diffraction pattern of the single crystalline form A is shown in Figure 7.
- 15 is shown in Figure 7.
7. The fumarate salt of any one of claims 1-6, wherein at least 90% by weight of the fumarate salt is single crystalline form A, characterized by an X-ray powder diffraction pattern which comprises peaks at:
- a)  $9.7^\circ$ ,  $16.7^\circ$ , and  $20.1^\circ \pm 0.2$  in  $2\theta$ ; or
- 20 b)  $8.2^\circ$ ,  $9.7^\circ$ ,  $16.7^\circ$ , and  $20.1^\circ \pm 0.2$  in  $2\theta$ ; or
- c)  $8.2^\circ$ ,  $9.7^\circ$ ,  $10.7^\circ$ ,  $11.5^\circ$ ,  $14.9^\circ$ ,  $16.7^\circ$ ,  $20.1^\circ$ , and  $23.5^\circ \pm 0.2$  in  $2\theta$ ; or
- d)  $8.2^\circ$ ,  $9.7^\circ$ ,  $10.7^\circ$ ,  $11.5^\circ$ ,  $13.6^\circ$ ,  $14.9^\circ$ ,  $16.7^\circ$ ,  $18.1^\circ$ ,  $18.8^\circ$ ,  $20.1^\circ$ ,  $23.5^\circ$ , and  $24.5^\circ \pm 0.2$  in  $2\theta$ .

8. The fumarate salt of any one of claims 1-5, wherein at least 90% by weight of the fumarate salt is single crystalline form B, and the X-ray powder diffraction pattern of the single crystalline form B is shown in Figure 8.
9. The fumarate salt of any one of claims 1-5 and 8, wherein at least 90% by weight of the fumarate salt is single crystalline form B, characterized by an X-ray powder diffraction pattern which comprises peaks at:
- a)  $11.9^\circ$  and  $14.9^\circ \pm 0.2$  in  $2\theta$ ; or
- b)  $11.9^\circ$ ,  $14.9^\circ$ ,  $18.7^\circ$ , and  $21.5^\circ \pm 0.2$  in  $2\theta$ ; or
- c)  $5.5^\circ$ ,  $5.9^\circ$ ,  $11.9^\circ$ ,  $14.9^\circ$ ,  $16.7^\circ$ ,  $17.4^\circ$ ,  $18.7^\circ$ ,  $21.5^\circ$ , and  $23.4^\circ \pm 0.2$  in  $2\theta$ .
10. The fumarate salt of any one of claims 1-5, wherein at least 75-80% by weight of the fumarate salt is single crystalline form C, and the X-ray powder diffraction pattern of the single crystalline form C is shown in Figure 9.
11. The fumarate salt of any one of claims 1-5 and 10, wherein at least 75-80% by weight of the fumarate salt is single crystalline form C, characterized by an X-ray powder diffraction pattern which comprises peaks at:
- a)  $16.8^\circ$ ,  $16.9^\circ$ , and  $19.9^\circ \pm 0.2$  in  $2\theta$ ; or
- b)  $9.8^\circ$ ,  $16.8^\circ$ ,  $16.9^\circ$ ,  $19.9^\circ$ , and  $23.5^\circ \pm 0.2$  in  $2\theta$ ; or
- c)  $9.7^\circ$ ,  $9.8^\circ$ ,  $11.7^\circ$ ,  $15.1^\circ$ ,  $16.8^\circ$ ,  $16.9^\circ$ ,  $19.9^\circ$ ,  $23.5^\circ$ , and  $23.7^\circ \pm 0.2$  in  $2\theta$ .
12. The fumarate salt of any one of claims 1-5, wherein at least 90% by weight of the fumarate salt is single crystalline form D, and the X-ray powder diffraction pattern of the single crystalline form D is shown in Figure 10.
13. The fumarate salt of any one of claims 1-5 and 12, wherein at least 90% by weight of the fumarate salt is single crystalline form D, characterized by an X-ray powder diffraction pattern which comprises peaks at:
- a)  $9.6^\circ$ ,  $12.8^\circ$ ,  $16.0^\circ$ , and  $22.0^\circ \pm 0.2$  in  $2\theta$ ; or
- b)  $9.6^\circ$ ,  $12.8^\circ$ ,  $16.0^\circ$ ,  $16.9^\circ$ ,  $21.2^\circ$ , and  $22.0^\circ \pm 0.2$  in  $2\theta$ ; or
- c)  $9.6^\circ$ ,  $12.8^\circ$ ,  $16.0^\circ$ ,  $16.9^\circ$ ,  $20.8^\circ$ ,  $21.2^\circ$ ,  $21.5^\circ$ , and  $22.0^\circ \pm 0.2$  in  $2\theta$ .
- d)  $9.6^\circ$ ,  $11.7^\circ$ ,  $12.0^\circ$ ,  $12.8^\circ$ ,  $16.0^\circ$ ,  $16.6^\circ$ ,  $16.9^\circ$ ,  $18.1^\circ$ ,  $19.2^\circ$ ,  $19.8^\circ$ ,  $20.7^\circ$ ,  $20.8^\circ$ ,  $21.2^\circ$ ,  $21.5^\circ$ ,  $22.0^\circ$ ,  $22.5^\circ$ ,  $24.0^\circ$ ,  $26.0^\circ$ , and  $29.8^\circ \pm 0.2$  in  $2\theta$ .

14. The fumarate salt of any one of claims 1-7, wherein at least 90% by weight of the fumarate salt is single crystalline form A, characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of 112 °C and 158 °C.
15. The fumarate salt of any one of claims 1-5, 8, and 9, wherein at least 90% by weight of the fumarate salt is single crystalline form B, characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of 58 °C and 162 °C.
16. The fumarate salt of any one of claims 1-5, 10, and 11, wherein at least 90% by weight of the fumarate salt is single crystalline form C, characterized by differential scanning calorimeter (DSC) peak phase transition temperatures of 62 °C and 156 °C.
17. The fumarate salt of any one of claims 1-5, 12, and 13, wherein at least 90% by weight of the fumarate salt is single crystalline form D, characterized by differential scanning calorimeter (DSC) peak phase transition temperature of 219°C.
18. A maleate salt of compound (I) represented by the following structural formula:



Compound (I)

- wherein the molar ratio between compound (I) and maleic acid is 1:1.
19. The maleate salt of claim 18, wherein at least 90% by weight of the salt is crystalline.
20. The maleate salt of claim 18 or 19, wherein at least 90% by weight of the salt is in a single crystalline form.
21. The maleate salt of any one of claims 18-20, wherein at least 99% by weight of the salt is crystalline.
22. The maleate salt of any one of claims 18-21, wherein at least 99% by weight of the salt is in a single crystalline form.
23. The maleate salt of any one of claims 18-22, wherein at least 90% by weight of the maleate salt is single crystalline form A, and the X-ray powder diffraction pattern of the single crystalline form A is shown in Figure 11.



24. The maleate salt of any one of claims 18-23, wherein at least 90% by weight of the maleate salt is single crystalline form A, characterized by an X-ray powder diffraction pattern which comprises peaks at:
- a)  $11.5^{\circ}$ ,  $12.6^{\circ}$ ,  $14.9^{\circ}$ , and  $15.1^{\circ} \pm 0.2$  in  $2\theta$ ; or
- 5 b)  $10.8^{\circ}$ ,  $11.5^{\circ}$ ,  $12.4^{\circ}$ ,  $12.6^{\circ}$ ,  $14.9^{\circ}$ ,  $15.1^{\circ}$ , and  $17.1^{\circ} \pm 0.2$  in  $2\theta$ ; or
- c)  $5.8^{\circ}$ ,  $10.8^{\circ}$ ,  $11.5^{\circ}$ ,  $12.4^{\circ}$ ,  $12.6^{\circ}$ ,  $14.9^{\circ}$ ,  $15.1^{\circ}$ ,  $17.1^{\circ}$ ,  $18.6^{\circ}$ ,  $23.5^{\circ}$ , and  $26.1^{\circ} \pm 0.2$  in  $2\theta$ ; or
- d)  $5.5^{\circ}$ ,  $5.8^{\circ}$ ,  $10.8^{\circ}$ ,  $11.5^{\circ}$ ,  $12.4^{\circ}$ ,  $12.6^{\circ}$ ,  $14.1^{\circ}$ ,  $14.9^{\circ}$ ,  $15.1^{\circ}$ ,  $16.7^{\circ}$ ,  $17.1^{\circ}$ ,  $17.8^{\circ}$ ,  $18.6^{\circ}$ ,  $19.5^{\circ}$ ,  $19.9^{\circ}$ ,  $21.9^{\circ}$ ,  $22.2^{\circ}$ ,  $23.0^{\circ}$ ,  $23.3^{\circ}$ ,  $23.5^{\circ}$ ,  $23.9^{\circ}$ , and  $26.1^{\circ} \pm 0.2$  in  $2\theta$ .
- 10 25. The maleate salt of any one of claims 18-24, wherein at least 90% by weight of the maleate salt is single crystalline form A, characterized by differential scanning calorimeter (DSC) peak phase transition temperature of  $219^{\circ}\text{C}$ .
26. A pharmaceutical composition comprising the fumarate salt of any one of claims 1-17 or the maleate salt of any one of claims 18-25, and a pharmaceutically acceptable
- 15 carrier or diluent, wherein at least 80% by weight of the salt is crystalline.
27. A method of treating a subject with cancer, comprising administering to the subject an effective amount of a salt of any one of claims 1-25 or a pharmaceutically composition thereof.
28. The method of claim 27, wherein the cancer is selected from the group consisting of
- 20 lung cancer, breast cancer, colon cancer, neuroblastoma, prostate cancer, melanoma, glioblastoma multiforme, ovarian cancer, lymphoma, leukemia, osteosarcoma, germinoma, glioma, fibrosarcoma, gastrointestinal sarcoma, fibrous histiocytoma, round cell sarcoma, synovial sarcoma, cervical cancer, anogenital cancer, head and neck cancer, and oropharyngeal cancer.
- 25 29. The method of claim 28, wherein the cancer is selected from the group consisting of lung cancer, breast cancer and colon cancer.
30. The method of claim 29, wherein the cancer is breast cancer.

Figure 1. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino) methyl) styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form A




Figure 2. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino) methyl) styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form B




Figure 3. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino) methyl) styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form C




Figure 4. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form D




Figure 5. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxy Spiro[cyclopropane-1,3'-indolin]-2'-one maleate form A




Figure 6. DSC thermogram of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one phosphate




Figure 7. XRPD of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form A






Figure 8. XRPD of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form B





Figure 9. XRPD of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form C



10/11

Figure 10. XRPD of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one fumarate form D





Figure 11. XRPD of (1R,2S)-(E)-2-(3-(4-((cis-2,6-dimethylmorpholino)methyl)styryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one maleate form A



## INTERNATIONAL SEARCH REPORT

International application No.

**PCT/CA2014/051001**

## A. CLASSIFICATION OF SUBJECT MATTER

IPC: **C07D 413/14** (2006.01), **A61K 31/5377** (2006.01), **A61P 35/00** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

C07D 413/14, A61K 31/5377, A61P 35/00

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

n/a

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Databases: STN, Intellect, Questel Orbit, Espacenet, PubMed, Scopus, Google scholar, ScienceDirect, and American Chemical Society publication search. Keywords: polo-like kinase inhibitors, PLK inhibitors, PLK4, fumaric acid salt and protein kinase inhibitors, fumaric acid salt and crystalline, pharmaceutically acceptable salts and fumarate, polo-like kinase inhibitors and salt.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US8481525 (SAMPSON, PB et al.) 09 July 2013 (09-07-2013) Whole document; cited in application	1-17, 26 and 27-30
Y	US8263596 (SAMPSON, PB et al.) 11 September 2012 (21-09-2012) Whole document; cited in application	1-17, 26 and 27-30
Y	US8481533 (SAMPSON, PB et al.) 09 July 2013 (09-07-2013) Whole document; cited in application	1-17, 26 and 27-30
Y	US8318727 (CAO, SX et al.) 27 November 2012 (27-11-2012) Whole document; cited in application	1-17, 26 and 27-30
Y	WO2012048411 (PAULS, H et al.) 19 April 2012 (19-04-2012) Whole document	1-17, 26 and 27-30

☒ Further documents are listed in the continuation of Box C.☒ See patent family annex.

* "A" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"I" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
--------------------------------------	--	--------------------------	--

Date of the actual completion of the international search  
3 December 2014 (03-12-2014)Date of mailing of the international search report  
22 January 2015 (22-01-2015)

Name and mailing address of the ISA/CA  
Canadian Intellectual Property Office  
Place du Portage I, C114 - 1st Floor, Box PCT  
50 Victoria Street  
Gatineau, Quebec K1A 0C9  
Facsimile No.: 001-819-953-2476

Authorized officer

Wendy Young (819) 934-0477

## INTERNATIONAL SEARCH REPORT

International application No.

**PCT/CA2014/051001**

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO2013053051 (PAULS, H et al.) 18 April 2013 (18-04-2013) Whole document	1-17, 26 and 27-30
Y	US7511059 (SCHULZE, V et al.) 31 March 2009 (31-03-2009) Whole document	1-17, 26 and 27-30
Y	“Conformational analysis and crystal structure of {[1-3-chloro-4-fluorobenzoyl]-4-fluoropiperidine-4-yl)methyl}[(5-methylpyridin-2-yl)methyl]amine, fumaric acid salt”. J.P.Ribet et al. <i>Spectrochimic Acta Part A</i> 2005, 62, 353-363 Whole document	1-17, 26 and 27-30
Y	WO2007110559 (ZEGARAC, M et al.) 04 October 2007 (04-10-2007) Whole document	1-17, 26 and 27-30
Y	WO2012121764 (GIDWANI, RM et al.) 13 September 2012 (13-09-2012) Whole document	1-17, 26 and 27-30
A,P	“Functional Characterization of CFI-400945, a Polo-like Kinase 4 inhibitor, as a Potential Anticancer agent”. Mason, JM et al. <i>Cancer Cell</i> August 11, 2014, 26, 163-176 whole document	1-17, 26 and 27-30
A,P	“The Discovery of Polo-like Kinase 4 Inhibitors: Identification of (1R,2S)-2-(3-((4-(((cis)-2,6-Dimethylmorpholino)methyl)stryryl)-1H-indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]2-one(CFI-400945) as a Potent, Orally Active Antitumor Agent”. Peter B Sampson et al. <i>Journal of Medicinal Chemistry</i> , May 27, 2014 ASAP article. Whole document	1-17, 26 and 27-30

## INTERNATIONAL SEARCH REPORT

International application No.

**PCT/CA2014/051001****Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of the first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
  
2. ☐ Claim Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
  
3. ☐ Claim Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

On the basis of i) type of pharmaceutical salt and ii) method of preparation as described in the originally-filed description, the International Search Authority has determined there is a lack of unity, a priori, in the present claims:

**Group A:** claims 1-17, 26 and 27-30(part) are directed to fumarate salt of compound (I), wherein such fumarate salt is further distinguished as i) amorphous, ii) crystalline form A, iii) crystalline form B, iv) crystalline form C and v) crystalline form D respectively, as well as pharmaceutical composition and medicinal use of the fumarate salt.

**Group B:** claims 18-25 and 27-30(part) are directed to maleate salt of compound (I), wherein such maleate salt is further distinguished as crystalline form A, as well as pharmaceutical composition and medicinal use of the maleate salt.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claim Nos.:
  
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim Nos.:

**Group A:** claims 1-17, 26 and 27-30(part) are directed to fumarate salt of compound (I), wherein such fumarate salt is further distinguished as i) amorphous, ii) crystalline form A, iii) crystalline form B, iv) crystalline form C and v) crystalline form D respectively, as well as pharmaceutical composition and medicinal use of the fumarate salt.

**Remark on Protest**

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.

**INTERNATIONAL SEARCH REPORT**  
Information on patent family members

International application No.  
**PCT/CA2014/051001**

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
US8481525B2	09 July 2013 (09-07-2013)	US2012149686A1	14 June 2012 (14-06-2012)
		AU2011238384A1	27 September 2012 (27-09-2012)
		CA2756568A1	14 October 2010 (14-10-2010)
		CA2791324A1	13 October 2011 (13-10-2011)
		CA2792641A1	13 October 2011 (13-10-2011)
		CN102892766A	23 January 2013 (23-01-2013)
		EA201270752A1	30 April 2013 (30-04-2013)
		EP2417127A1	15 February 2012 (15-02-2012)
		EP2417127A4	29 August 2012 (29-08-2012)
		EP2417127B1	26 February 2014 (26-02-2014)
		EP2556070A1	13 February 2013 (13-02-2013)
		EP2556070A4	23 October 2013 (23-10-2013)
		EP2556071A1	13 February 2013 (13-02-2013)
		EP2556071A4	04 September 2013 (04-09-2013)
		ES2465971T3	09 June 2014 (09-06-2014)
		JP2013523784A	17 June 2013 (17-06-2013)
		JP5442906B2	19 March 2014 (19-03-2014)
		JP2012522729A	27 September 2012 (27-09-2012)
		KR20130108065A	02 October 2013 (02-10-2013)
		MX2012011516A	08 March 2013 (08-03-2013)
		NZ602350A	30 May 2014 (30-05-2014)
		SG183875A1	30 October 2012 (30-10-2012)
		TW201134471A	16 October 2011 (16-10-2011)
		US2011263598A1	27 October 2011 (27-10-2011)
		US8263596B2	11 September 2012 (11-09-2012)
		US2012264800A1	18 October 2012 (18-10-2012)
		US8481533B2	09 July 2013 (09-07-2013)
		US2013096301A1	18 April 2013 (18-04-2013)
		US2014045822A1	13 February 2014 (13-02-2014)
		US2014045838A1	13 February 2014 (13-02-2014)
		WO2010115279A1	14 October 2010 (14-10-2010)
		WO2011123946A1	13 October 2011 (13-10-2011)
		WO2011123946A8	08 December 2011 (08-12-2011)
		WO2011123947A1	13 October 2011 (13-10-2011)
		WO2011123947A8	22 December 2011 (22-12-2011)
US8263596B2	11 September 2012 (11-09-2012)	US2011263598A1	27 October 2011 (27-10-2011)
		AU2011238384A1	27 September 2012 (27-09-2012)
		CA2756568A1	14 October 2010 (14-10-2010)
		CA2791324A1	13 October 2011 (13-10-2011)
		CA2792641A1	13 October 2011 (13-10-2011)
		CN102892766A	23 January 2013 (23-01-2013)
		EA201270752A1	30 April 2013 (30-04-2013)
		EP2417127A1	15 February 2012 (15-02-2012)
		EP2417127A4	29 August 2012 (29-08-2012)
		EP2417127B1	26 February 2014 (26-02-2014)
		EP2556070A1	13 February 2013 (13-02-2013)
		EP2556070A4	23 October 2013 (23-10-2013)
		EP2556071A1	13 February 2013 (13-02-2013)
		EP2556071A4	04 September 2013 (04-09-2013)
		ES2465971T3	09 June 2014 (09-06-2014)
		JP2013523784A	17 June 2013 (17-06-2013)
		JP5442906B2	19 March 2014 (19-03-2014)
		JP2012522729A	27 September 2012 (27-09-2012)
		KR20130108065A	02 October 2013 (02-10-2013)
		MX2012011516A	08 March 2013 (08-03-2013)
		NZ602350A	30 May 2014 (30-05-2014)
		SG183875A1	30 October 2012 (30-10-2012)
		TW201134471A	16 October 2011 (16-10-2011)
		US2012149686A1	14 June 2012 (14-06-2012)
		US8481525B2	09 July 2013 (09-07-2013)
		US2012264800A1	18 October 2012 (18-10-2012)
		US8481533B2	09 July 2013 (09-07-2013)
		US2013096301A1	18 April 2013 (18-04-2013)
		US2014045822A1	13 February 2014 (13-02-2014)
		US2014045838A1	13 February 2014 (13-02-2014)
		WO2010115279A1	14 October 2010 (14-10-2010)
		WO2011123946A1	13 October 2011 (13-10-2011)
		WO2011123946A8	08 December 2011 (08-12-2011)



## INTERNATIONAL SEARCH REPORT

International application No.

**PCT/CA2014/051001**

_US8481533B2	09 July 2013 (09-07-2013)	US2012264800A1	18 October 2012 (18-10-2012)
		AU2011238384A1	27 September 2012 (27-09-2012)
		CA2756568A1	14 October 2010 (14-10-2010)
		CA2791324A1	13 October 2011 (13-10-2011)
		CA2792641A1	13 October 2011 (13-10-2011)
		CN102892766A	23 January 2013 (23-01-2013)
		EA201270752A1	30 April 2013 (30-04-2013)
		EP2417127A1	15 February 2012 (15-02-2012)
		EP2417127A4	29 August 2012 (29-08-2012)
		EP2417127B1	26 February 2014 (26-02-2014)
		EP2556070A1	13 February 2013 (13-02-2013)
		EP2556070A4	23 October 2013 (23-10-2013)
		EP2556071A1	13 February 2013 (13-02-2013)
		EP2556071A4	04 September 2013 (04-09-2013)
		ES2465971T3	09 June 2014 (09-06-2014)
		JP2013523784A	17 June 2013 (17-06-2013)
		JP5442906B2	19 March 2014 (19-03-2014)
		JP2012522729A	27 September 2012 (27-09-2012)
		KR20130108065A	02 October 2013 (02-10-2013)
		MX2012011516A	08 March 2013 (08-03-2013)
		NZ602350A	30 May 2014 (30-05-2014)
		SG183875A1	30 October 2012 (30-10-2012)
		TW201134471A	16 October 2011 (16-10-2011)
		US2011263598A1	27 October 2011 (27-10-2011)
		US8263596B2	11 September 2012 (11-09-2012)
		US2012149686A1	14 June 2012 (14-06-2012)
		US8481525B2	09 July 2013 (09-07-2013)
		US2013096301A1	18 April 2013 (18-04-2013)
		US2014045822A1	13 February 2014 (13-02-2014)
		US2014045838A1	13 February 2014 (13-02-2014)
		WO2010115279A1	14 October 2010 (14-10-2010)
		WO2011123946A1	13 October 2011 (13-10-2011)
		WO2011123946A8	08 December 2011 (08-12-2011)
		WO2011123947A1	13 October 2011 (13-10-2011)
		WO2011123947A8	22 December 2011 (22-12-2011)
US8318727B2	27 November 2012 (27-11-2012)	US2011082111A1	07 April 2011 (07-04-2011)
		AR071729A1	14 July 2010 (14-07-2010)
		AU2008304417A1	02 April 2009 (02-04-2009)
		AU2008304417B2	18 July 2013 (18-07-2013)
		CA2699607A1	02 April 2009 (02-04-2009)
		CA2700295A1	02 April 2009 (02-04-2009)
		CN101917995A	15 December 2010 (15-12-2010)
		CN103122001A	29 May 2013 (29-05-2013)
		CO6270231A2	20 April 2011 (20-04-2011)
		CR11370A	16 July 2010 (16-07-2010)
		DOP2010000091A	31 July 2010 (31-07-2010)
		EA201070395A1	29 October 2010 (29-10-2010)
		EA019487B1	30 April 2014 (30-04-2014)
		ECSP10010129A	29 June 2010 (29-06-2010)
		EP2197442A1	23 June 2010 (23-06-2010)
		EP2197442B1	12 September 2012 (12-09-2012)
		EP2205241A1	14 July 2010 (14-07-2010)
		EP2205241B1	21 May 2014 (21-05-2014)
		EP2564850A1	06 March 2013 (06-03-2013)
		EP2564850B1	13 August 2014 (13-08-2014)
		ES2488966T3	01 September 2014 (01-09-2014)
		HK1145144A1	29 August 2014 (29-08-2014)
		JP2010540463A	24 December 2010 (24-12-2010)
		JP5372939B2	18 December 2013 (18-12-2013)
		JP2010540464A	24 December 2010 (24-12-2010)
		KR20100087292A	04 August 2010 (04-08-2010)
		KR20140097440A	06 August 2014 (06-08-2014)
		MA31763B1	01 October 2010 (01-10-2010)
		MX2010003244A	21 April 2010 (21-04-2010)
		MX2010003249A	09 November 2010 (09-11-2010)
		NZ584760A	30 March 2012 (30-03-2012)
		PE07102009A1	15 July 2009 (15-07-2009)
		TW200927135A	01 July 2009 (01-07-2009)
		TWI436769B	11 May 2014 (11-05-2014)
		UA99739C2	25 September 2012 (25-09-2012)
		US2009281092A1	12 November 2009 (12-11-2009)

## INTERNATIONAL SEARCH REPORT

International application No.

**PCT/CA2014/051001**

WO2012048411A1	19 April 2012 (19-04-2012)	None	
WO2013053051A1	18 April 2013 (18-04-2013)	WO2013053051A1 CA2850394A1 EP2766352A1 TW201427970A US2014051679A1 WO2014056083A1	18 April 2013 (18-04-2013) 18 April 2013 (18-04-2013) 20 August 2014 (20-08-2014) 16 July 2014 (16-07-2014) 20 February 2014 (20-02-2014) 17 April 2014 (17-04-2014)
US7511059B2	31 March 2009 (31-03-2009)	US2006223833A1 AR052370A1 AU2006210153A1 BRPI0606140A2 CA2596967A1 CN101155791A CR9323A DE102005005395A1 DOP2006000024A EP1844027A1 GT200600039A IL185023D0 JP2008529985A KR20070100830A MX2007009387A NO20074448A PA8661701A1 PE10852006A1 UY29358A1 WO2006082107A1 ZA200707520A	05 October 2006 (05-10-2006) 14 March 2007 (14-03-2007) 10 August 2006 (10-08-2006) 02 June 2009 (02-06-2009) 10 August 2006 (10-08-2006) 02 April 2008 (02-04-2008) 21 February 2008 (21-02-2008) 10 August 2006 (10-08-2006) 15 August 2006 (15-08-2006) 17 October 2007 (17-10-2007) 06 September 2006 (06-09-2006) 03 December 2007 (03-12-2007) 07 August 2008 (07-08-2008) 11 October 2007 (11-10-2007) 16 August 2007 (16-08-2007) 31 October 2007 (31-10-2007) 07 December 2006 (07-12-2006) 11 November 2006 (11-11-2006) 31 July 2006 (31-07-2006) 10 August 2006 (10-08-2006) 26 November 2008 (26-11-2008)
WO2007110559A1	04 October 2007 (04-10-2007)	WO2007110559A1 GB0606234D0	04 October 2007 (04-10-2007) 10 May 2006 (10-05-2006)
WO2012121764A1	13 September 2012 (13-09-2012)	WO2012121764A1 CN103476770A EA201390772A1 EP2643314A1 IL226477D0 JP2014511336A KR20130105675A US2014051713A1	13 September 2012 (13-09-2012) 25 December 2013 (25-12-2013) 29 November 2013 (29-11-2013) 02 October 2013 (02-10-2013) 31 July 2013 (31-07-2013) 15 May 2014 (15-05-2014) 25 September 2013 (25-09-2013) 20 February 2014 (20-02-2014)